. Author manuscript; available in PMC: 2013 Nov 7.

Published in final edited form as: Neuropharmacology. 2010 Sep 17;60(0):10.1016/j.neuropharm.2010.09.011. doi: 10.1016/j.neuropharm.2010.09.011

Table II.

Combination Effects of PG01042 and PG01037.

Drug regimen	%Reduction
PG01042	35.1 ± 9.1
PG01037	21.6 ± 4.4
PG01042 and PG01037	44.6 ± 6.9
buspirone	34.8 ± 6.2
PG01042 and buspirone	50.5 ± 7.0
PG01037 and buspirone	65.2 ± 7.9

The PG01042 and PG01037 were administered alone or concurrently to evaluate their effect on AIM scores. The test doses were a) PG01042 at 3 mg/kg, b) PG01037 at 3 mg/kg or c) buspirone at 1 mg/kg. The mean values ± S.E.M. for the normalized reduction (percent reduction) of total AIMs values is shown for n = 12. Test compounds were administered by i.p. injection with a constant dose of L-dopa (8 mg/kg) and benserazide (8 mg/kg).